Riskpilot← Back to searchSign inGet full accessFreya Biosciences ApS
APSActiveCVR 41257547Fruebjergvej 3Manufacture of pharmaceutical preparations · NACE 2120Est. 202017 employees
Revenue 2024
DKK -6,7M
+24% vs 2023
EBITDA margin
1373.8%
-5% vs 2023
Equity ratio
92.0%
Financial strength
Net profit 2024
DKK -85,4M
-5% vs 2023
| Revenue | DKK -6,7M | +24% |
| EBITDA | DKK -91,5M | -5% |
| Net profit | DKK -85,4M | -5% |
| Total assets | DKK 141,4M | +73% |
| Equity | DKK 130,1M | +73% |
| Employees | 17 | — |
Legal name
Freya Biosciences ApS
CVR number
41257547
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
23. marts 2020
Share capital
DKK 1.175.250
Employees
17 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med et medlem af bestyrelsen, af bestyrelsens formand i forening med et medlem af direktionen, eller af den samlede bestyrelse
Company purpose
Selskabets formål er at udvikle og drive virksomhed inden for handel med farmaceutiske produkter og udstyr samt anden i forbindelse hermed stående virksomhed
Address
Fruebjergvej 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -577 | 0 | -16.628 | -5.366 | -6.657 |
| Staff expenses | -873 | -5.890 | -7.155 | -14.302 | -18.999 |
| EBITDA | -2.103 | -22.635 | -39.181 | -87.196 | -91.459 |
| Depreciation & amort. | -15 | -123 | -123 | -91 | -90 |
| EBIT | -2.118 | -22.759 | -39.304 | -87.287 | -91.549 |
| Net financials | -35 | -131 | 196 | 691 | 615 |
| Profit before tax | -2.153 | -22.889 | -39.108 | -86.596 | -90.934 |
| Tax | -258 | -2.483 | -6.951 | -5.500 | -5.500 |
| Net profit | -1.895 | -20.406 | -32.157 | -81.096 | -85.434 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 17.194 | 32.367 | 16.376 | 81.766 | 141.431 |
| Equity | 16.761 | 28.411 | -3.745 | 75.005 | 130.067 |
| Long-term debt | 0 | 0 | 13.014 | 0 | 0 |
| Short-term debt | 433 | 3.955 | 7.107 | 6.761 | 11.364 |
| Total debt | 433 | 3.955 | 20.121 | 6.761 | 11.364 |
EBITDA margin
-9145923400.0%
This company
15.8%
Market median
-57885591239% vs market
20202024
Equity ratio
92.0%
This company
38.2%
Market median
+141% vs market
20202024
Return on equity
-65.7%
This company
18.4%
Market median
-457% vs market
20202024
Net profit margin
-8543429400.0%
This company
8.1%
Market median
-105474437137% vs market
20202024
Asset turnover
-0.05×
This company
1.12×
Market median
-104% vs market
20202024
Debt / equity
0.09×
This company
0.62×
Market median
+85% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-03-23 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RR Management | Management | 2023 | — | — |
CD Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
MC Founder | Founder | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 20.0% | 20.0% | 2024 | |
Danmarks Eksport- og Investeringsfond | Company | 10.0% | 10.0% | 2024 |
| Individual | 10.0% | 10.0% | 2024 | |
| Individual | 10.0% | 10.0% | 2025 | |
| Individual | 10.0% | 10.0% | 2024 | |
| Individual | 5.0% | 5.0% | 2023 | |
VÆKSTFONDEN | Company | 5.0% | 5.0% | 2023 |
ABT Consult ApS | Company | 5.0% | 5.0% | 2020 |
R. Rich Holding ApS | Company | 5.0% | 5.0% | 2020 |
Curanthia Holdings ApS | Company | 5.0% | 5.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Freya Biosciences ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Randi Rich | Management | 0 companies |
| Colleen Denise Acosta | Chief Executive Officer | 0 companies |
| MBFH Consulting SAS | Founder | 0 companies |
| Mark Smith | Board of Directors | 0 companies |
| Claudia Maria Colciago | Board of Directors | 0 companies |
| Nicholas Haft | Board of Directors | 0 companies |
| David Lawrence Stern | Board of Directors | 0 companies |
| Henrijette Elsebeth Richter | Board of Directors | 0 companies |
| Peter Finsel Bisgaard | Chairman | 0 companies |
| Thomas Gundelund Rasmussen | Board of Directors | 0 companies |
| Johannes Epeüs Theodoor van Hylckama Vlieg | Board of Directors | 0 companies |